This site is intended for
Healthcare Providers Only

What is EXPAREL®?

About EXPAREL for postsurgical pain management

EXPAREL — The Only Single-Dose Local Analgesic That Controls Pain for Up to 72 Hours

EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®. A single intraoperative injection treats pain at the source with reduced opioid requirements for up to 72 hours.1

Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures. The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.

When used as part of a multimodal treatment regimen, EXPAREL can provide non-opioid pain control that lasts as long as the most intense postsurgical pain, without the need for catheters, pumps, or other delivery devices.2

EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.1

Efficacy and Safety

The efficacy of EXPAREL was compared to placebo in two multicenter, randomized, double-blinded clinical trials conducted in a soft tissue (excisional hemorrhoidectomy) and an orthopedic (bunionectomy) surgical model.1

The safety of EXPAREL has been evaluated in 21 clinical trials which include over 1300 subjects in the safety database. EXPAREL administered locally into the surgical site was evaluated in 10 randomized, double-blind clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 mg to 532 mg of EXPAREL.1

View the reimbursement guide for EXPAREL

Reimbursement Guide

View the reimbursement guide for EXPAREL View

Sign up to receive updates on EXPAREL

Sign Up

Sign up to receive updates on EXPAREL. > Sign Up

How to use EXPAREL

How to Use EXPAREL

Learn about the technique clinicians are using to administer EXPAREL. > More

These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.

To report an adverse event, e-mail or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, contact Medical Information at or 1-855-RX-EXPAREL (1-855-793-9727).


  1. EXPAREL [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.
  2. Beauregard L, Pomp A, et al. Severity and impact of pain after day-surgery. Can J Anaesth.1998;45(4):304-311.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.

Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.

Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.

In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.


Sign up to receive updates on EXPAREL.


First name*

Last name*


ZIP code*

Providing the optional information about you below enables us to provide information geared to your needs.


Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy.

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.



Your name:*

Your colleague's name:*

Your colleague's e-mail address:*

To learn about our use of your information and your rights, please consult our Privacy Policy.

Your email has been sent.
Thank you!

The email address you entered was invalid.

Unfortunately, your email could not be sent at this time.